Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

@article{Sparreboom1999ClinicalPO,
  title={Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.},
  author={Alex Sparreboom and A. S. T. Planting and Roxanne C. Jewell and Maria van der Burg and Ate van der Gaast and Peter J de Bruijn and Walter J. Loos and Kees Nooter and Lance Chandler and Elaine M Paul and Paul S. Wissel and J. F. Verweij},
  journal={Anti-cancer drugs},
  year={1999},
  volume={10 8},
  pages={
          719-28
        }
}
Previous clinical investigations with doxorubicin indicated that modulators of P-glycoprotein dramatically decrease the systemic clearance of the drug, which complicates the interpretation of toxicity and response data. In the present study, we examined the pharmacokinetics of doxorubicin and GF120918, a novel potent P-glycoprotein inhibitor, in cancer patients in a search for more selective modulation of multidrug resistance (MDR). Seven cohorts (46 patients) received sequential treatments… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…